Introduction
Blood stem cell transplantation offers a curative option for patients with severe sickle cell disease. While the majority of patients with an HLA-identical sibling can be cured, the vast majority of patients do not have a suitable donor. On the other hand, most patients have a haploidentical (half-matched) parent, child, or sibling who can serve as the donor. This protocol uses a nonmyeloablative haploidentical approach for patients with severe sickle cell disease. The goal of the study is to reverse sickle cell disease with a decreased risk of toxicity.
To get started:
- Navigate through the menu to learn more about the study.
- Log in to the application and fill out questionnaires.
Please contact us if you have any questions or concerns.